Which de novo lesions are more likely to benefit from drug-coated balloon angioplasty? Layered coronary plaques, like the one depicted in the figure. They can be recognized in optical frequency domain imaging by their heterogeneous tissue layers with different optical densities

In the 18th Expert Consensus Document, now available in the Journal, the European Bifurcation Club (EBC) reviews and describes a series of tips and tricks which can help to optimize angiography-guided PCI for coronary bifurcation lesions.

These include:
- A thorough analysis

Increasingly, social media features photos of interventional cardiology groups proudly showcasing a procedure performed for the first time in a specific hospital. These photos celebrate the results of hard team work and show rightfully proud faces, often including not only

Evidence for short DAPT after an ACS in high bleeding risk patients undergoing PCI is limited.

In this study, high bleeding risk patients undergoing non-complex PCI for either NSTE-ACS or chronic coronary syndrome experienced similar ischemic risk and reduced bleeding with

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

A quick recap of new randomized trials in the fields of coronary and valvular interventions you may have missed this year at #EuroPCR if you were only watching live cases or attending practical sessions.

NOTION-2 did not demonstrate the noninferiority of TAVI compared to surgery for the primary endpoint at 1 year. Due to fewer events than anticipated in the surgery group, the trial lost statistical power, resulting in widened confidence intervals that crossed both the

EuroIntervention will be releasing a series of articles in conjunction with #EuroPCR 2024. Find below details on all the simultaneous publications and their release dates.

Top five 2024 clichés in cardiology (updated, and counting):

- “Difficult to cover this topic in x minutes” (x can be 5, 10, 20 minutes or three days, they will say it anyway)
- “Great talk, congratulations for staying on time” (which, I mean, should be normal)
- 'Did you have a

The special #EuroPCR 2024 issue of EuroIntervention is online, and there is something to suit everyone's taste. Here are some of the questions addressed or discussed this week.

Invasive management and decision making
· Did sex modify the outcomes of the ISCHEMIA trial?
· Can

The identification and management of patients at high bleeding risk (HBR) undergoing TAVI are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making.

The Valve Academic Research Consortium

There are three major late-breaking trials presented this year at #EuroPCR (May 15, 8.30-10.00 AM CEST).

The first trial is called REC-CAGEFREE II. It is the first randomized study of antiplatelet monotherapy after PCI with drug-coated balloons. It will test a stepwise regimen

In this multicenter registry of 10,872 patients undergoing TAVI, baseline ejection fraction was ≤30% in 914 (8.4%) patients. Of them, the left ventricle recovered in 59.5%, including 26.7% patients whose left ventricle function normalized completely.

No recovery was associated

#EuroPCR 2024 is fast approaching and to prepare for the Course, this year we have prepared the #EIJchallenge , which will put your knowledge of the journal and cardiovascular medicine to the test.

It will unfold in 2 parts: an online challenge on social media (Level 1) and then

What is the optimal antiplatelet regimen in patients with ACS undergoing PCI who are at both high bleeding and ischemic risks (i.e., “birisk”)?

In the double-blind, randomized OPT-BIRISK trial, including 7758 PCI-treated birisk patients with ACS who completed 9 to 12 months of